IPP Bureau
Wegovy delivers consistent weight loss & heart benefits for women across menopause: Novo Nordisk study
By IPP Bureau - May 14, 2026
Nearly one in five women worldwide are now living with obesity
Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook
By IPP Bureau - May 14, 2026
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push
By IPP Bureau - May 14, 2026
Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
Neuland Laboratories posts blockbuster FY26 performance
By IPP Bureau - May 14, 2026
Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth
By IPP Bureau - May 14, 2026
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI
By IPP Bureau - May 14, 2026
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
Revvity wins FDA clearance for total testosterone test
By IPP Bureau - May 14, 2026
Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation
By IPP Bureau - May 14, 2026
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
Roche wins CE mark for Alzheimer’s blood test that could transform early diagnosis
By IPP Bureau - May 13, 2026
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Breakthrough wearable heart failure therapy enables earlier hospital discharge: UK trial
By IPP Bureau - May 13, 2026
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy
By IPP Bureau - May 13, 2026
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
Industry-academia partnership expands access to advanced life sciences analytics for Indian researchers
By IPP Bureau - May 13, 2026
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
Mankind’s Rajeev Juneja contributes Rs. 9.17 crore to National Defence Fund
By IPP Bureau - May 13, 2026
This marks the second consecutive year that Juneja has made a personal contribution towards supporting the armed forces
